Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
20 results
  • Lung Cancer, Colorectal Cancer, Melanoma, Pancreatic Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations (View details on clinicaltrial.gov)

  • Bladder Cancer, Pancreatic Cancer, Sarcoma, Gastric (Stomach) Cancer, Endometrial Cancer, Liver Cancer, Esophageal Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on clinicaltrial.gov)

  • Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Breast Cancer, Pancreatic Cancer

22-015          Phase I

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a SA and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Gastric (Stomach) Cancer, Pancreatic Cancer, Colorectal Cancer

22-129          Phase II

A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3) (View details on clinicaltrial.gov)

  • Pancreatic Cancer, Gastric (Stomach) Cancer, Lung Cancer, Ovarian Cancer, Breast Cancer

22-368          Phase II

A Phase 2 Study of VLS-101 in Patients with Solid Tumors (View details on clinicaltrial.gov)

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

20-671          Phase II

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation (View details on clinicaltrial.gov)

  • Cervical Cancer, Breast Cancer, Ovarian Cancer, Bladder Cancer, Chordoma, Esophageal Cancer, Pancreatic Cancer, Endometrial Cancer, Melanoma, Lung Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on clinicaltrial.gov)

  • Pancreatic Cancer

20-607          Phase II

A phase II, open label, randomized, parallel arm study of NIS793 (with or without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) (View details on clinicaltrial.gov)

Showing 1 - 10 of 20 results